 Centogene N.V CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that Mr. Oved Amitay will be stepping down as Chief Business Officer CBO and leaving the Company effective May 31, 2020. Mr. Amitay will continue his work for rare diseases patients in the non-profit sector, where he will serve as Chief Executive Officer of a patient advocacy organization. 